Antithrombotic Treatment Resistance in Multiple Myeloma Likely Multifactorial
Researchers sought to determine the factors involved in the resistance to antithrombotic therapy that is observed among patients with multiple myeloma.
Researchers sought to determine the factors involved in the resistance to antithrombotic therapy that is observed among patients with multiple myeloma.
The rate of minimal residual disease negativity was 62% after induction.
Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.
Researchers sought to identify socioeconomic and demographic factors related to adherence to oral therapies in patients with multiple myeloma.
Researchers sought to determine whether post-transplant carfilzomib, lenalidomide, and dexamethasone would have superior PFS in patients with multiple myeloma.
Adding isatuximab to carfilzomib and dexamethasone significantly improved progression-free survival at a median follow-up of 44 months.
Researchers sought to characterize features of multiple myeloma cells that may be involved in treatment resistance to bortezomib.
The overall response rate was 100%, and the 18-month progression-free survival rate was 53%.
Transplant after a 3-drug induction regimen can prolong progression-free survival, compared with triplet induction alone, in patients with multiple myeloma.
Researchers sought to identify predictors of movement and neurocognitive treatment-emergent adverse events in patients undergoing CAR-T therapy with ciltacabtagene autoleucel.